Related Experiment Video
Updated: May 31, 2026
06:51
A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
Treatment Target Discovery From Vasculo-Protective Phenotypes.
1Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Journal of Lipid and Atherosclerosis
|May 29, 2026
Summary
Genetic studies reveal that Cdkal1 deficiency in the liver boosts cholesterol transport. This finding offers new therapeutic targets for cardiovascular diseases and drug development.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Genetic studies and bioinformatics accelerate the discovery of drug targets, particularly genes and proteins.
- Research into protective lipid profiles has identified novel therapeutic targets and driven drug development.
- High-density lipoprotein (HDL)-dependent cholesterol transport is a key area of atherosclerosis research.
Purpose of the Study:
- To explore the association between hepatic Cdkal1 deficiency and cholesterol transport.
- To identify novel therapeutic targets and inform drug development for cardiovascular conditions.
Main Methods:
- Genetic analysis of populations with specific phenotypes.
- Bioinformatic analysis of genetic data.
- Biochemical studies investigating gene and protein functions.
Main Results:
- A recent study reported an association between hepatic Cdkal1 deficiency and increased centripetal cholesterol transport.
- Cdkal1 plays a role in regulating cholesterol transport pathways.
Conclusions:
- Hepatic Cdkal1 deficiency presents a potential therapeutic target for managing cholesterol transport.
- Further genetic analyses of diverse populations with vasculo-protective phenotypes are expected to yield additional treatment targets and drug development opportunities.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...